The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector ...

In his first public comments since one of his executives was shot to death, UnitedHealth Group CEO Andrew Witty said the ...

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...